Achieve Life Sciences' nicotine dependence treatment under FDA review
Source: SeekingAlpha
2025-09-03 10:00:01 ET
More on Achieve Life Sciences
- Achieve Life Sciences, Inc. (ACHV) Q2 2025 Earnings Call Transcript
- Achieve Life Sciences: Nearing Commercialization Of A Best-In-Class Pharmaceutical Product For Smoking Cessation
- Achieve Life Sciences Q2 2025 Earnings Preview
- Achieve Life Sciences stock falls after pricing capital raise of $45M via securities offering
- Seeking Alpha’s Quant Rating on Achieve Life Sciences
Read the full article on Seeking Alpha
For further details see:
Achieve Life Sciences' nicotine dependence treatment under FDA review
Achieve Life Sciences Inc.
NASDAQ: ACHV
ACHV Trading
-2.55% G/L:
$4.20 Last:
297,398 Volume:
$4.25 Open:
ACHV Latest News
ACHV Stock Data
$234,761,887
51,636,968
N/A
28
N/A
Biotechnology & Life Sciences
Healthcare
CA
Bothell
